



FDA-AACR Workshop on HOW MUCH IS ENOUGH? TRIAL DESIGNS FOR TREATMENT REGIMENS WITH MULTIPLE PHASES

May 9, 2024, 9 a.m.–4 p.m. | Bethesda, MD

DISCLOSURE OF FINANCIAL RELATIONSHIPS

In compliance with the standards set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the American Association for Cancer Research (AACR) that the information presented at CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products or services used by or on patients.

Relationships are abbreviated as follows: E, Employment; FO, Fiduciary Officer; IC, Independent Contractor; S, Stock; SO, Stock Option; OS, Other Securities; OBO, Other Business Ownership; GC, Grant/Contract; T, Travel; GI, Gift; P, Patent; TM, Trademark; C, Copyright; OIP, Other Intellectual Property; O, Other

Last Name	First Name	All Relationships	Type	Role
Akinboro	Oladimeji	No Relationships		Speaker
Amatya	Anup	No Relationships		Speaker
Amiri-Kordestani	Laleh	No Relationships		Speaker
Anagnostou	Valsamo	AstraZeneca, Bristol-Myers Squibb, Delfi Diagnostics	GC, GC, GC	Speaker
Arthur	Ronald	No Relationships		Staff
Axelson	Michael	Eli Lilly and Company, Eli Lilly and Company	E, S	Speaker
Bhatnagar	Vishal	No Relationships		Speaker
Brown	Thelma	No Relationships		Speaker
DeClaro	Angelo	No Relationships		Speaker
Forde	Patrick	Janssen Global Services, LLC, Merck, Regeneron Pharmaceuticals, LUNgevity Foundation, Flame Biosciences, AstraZeneca, F-Star, Novartis, G1 Therapeutics, BioNTech, SANOFI PASTEUR INC., Bristol-Myers Squibb, Novartis, Daiichi Sankyo Company, Genentech, Polaris, Surface Oncology, Bristol-Myers Squibb, AstraZeneca, Iteos, Amgen	IC, IC, GC, IC, IC, IC, IC, IC, IC, GC, IC, IC, GC, IC, IC, IC, GC, GC, IC, IC	Speaker
Gause	Christine	Merck & Co., Inc., Merck & Co., Inc.	E, S	Speaker
George	Manju	Amgen, CRISPR Therapeutics AG, Johnson & Johnson Health Care Systems Inc., Natera, Pfizer	S, S, S, S, S	Speaker



FDA-AACR Workshop on HOW MUCH IS ENOUGH? TRIAL DESIGNS FOR TREATMENT REGIMENS WITH MULTIPLE PHASES

May 9, 2024, 9 a.m.–4 p.m. | Bethesda, MD

DISCLOSURE OF FINANCIAL RELATIONSHIPS

Last Name	First Name	All Relationships	Type	Role
Giaccone	Giuseppe	Amgen Inc.	E	Speaker
Gormley	Nicole	No Relationships		Speaker
Gray	Jhanelle	Oncocyte, Inivata, Gilead Sciences Inc, Blueprint Medicines Corporation, Bristol Myers Squibb Company, AstraZeneca, GI Therapeutics, Daiichi Sankyo Company, Pfizer, Axiom HC Strategies, Boehringer Ingelheim, Ludwig Institute of Cancer Research, Janssen Scientific Affairs, LLC, AbbVie, EMD Serono, Triptych Health Partners, Jazz Pharmaceuticals Inc., Merck, Novartis, Celgene Corporation, Moffitt Cancer Center, Loxo Oncology, Sanofi Pharmaceuticals, Takeda Pharmaceuticals	IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, O, IC, IC, IC, IC, IC, IC, IC, IC, E, IC, IC, IC	Speaker
Haddock Lobo Goulart	Bernardo	No Relationships		Speaker
Herbst	Roy	EMD Serrano, NextCure, Society for Immunotherapy of Cancer, Merck, Abbvie Pharmaceuticals, NextCure, Janssen Biotech, IMAB Biopharma, Ribon Therapeutics, Ocean Biomedical, Genentech/Roche, Checkpoint Therapeutics, Candel Therapeutics, AstraZeneca, American Association for Cancer Research, Seattle Genetics, Oncocyte, DynamiCure Biotechnology, OncternalÂ Therapeutics, Eli Lilly and Company, AstraZeneca, Cybrexa Therapeutics, eFFECTOR Therapeutics, Junshi Pharmaceuticals, Xencor Inc, Regeneron Pharmaceuticals, Pfizer, Gilead Research Foundation, International Association for the Study of Lung Cancer, Immunocore, Normunity, Novartis, Loxo Oncology, Immune-Onc Therapeutics, Merck, Bolt Biotherapeutics, SANOFI PASTEUR INC., Mirati Therapeutics, Bristol-Myers Squibb, HiberCell, Eli Lilly and Company, Johnson & Johnson Health Care Systems Inc.	IC, IC, IC, GC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, GC, GC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC	Speaker
Hirsch	Fred	Amgen, SANOFI US SERVICES INC., Daiichi Sankyo Company, Icahn School of Medicine at Mount Sinai, Nectin Therapeutics, Novartis, Regeneron Pharmaceuticals, OncoCyte, Genentech, AstraZeneca, Bristol-Myers Squibb	IC, IC, IC, E, IC, IC, IC, IC, IC, IC, IC	Speaker
Horiba	Naomi	No Relationships		Speaker
Jaffee	Elizabeth	Abmeta Therapeutics, Dragonfly Therapeutics, Adventris, Lustgarten Foundation, HDT Bio, Neuvogen, NeoTx, Mestag Therapeutics, CPRIT, Break Through Cancer, Orgenesis, Achilles Therapeutics, Parker Institute for Cancer Immunotherapy, Medically Home	OBO, IC, OBO, IC, IC, IC, IC, IC, IC, IC, O, IC, IC, IC	Program Committee, Speaker



FDA-AACR Workshop on HOW MUCH IS ENOUGH? TRIAL DESIGNS FOR TREATMENT REGIMENS WITH MULTIPLE PHASES

May 9, 2024, 9 a.m.–4 p.m. | Bethesda, MD

DISCLOSURE OF FINANCIAL RELATIONSHIPS

Last Name	First Name	All Relationships	Type	Role
Kidwell	Kelley	No Relationships		Speaker
Kris	Mark	Bristol Myers Squibb Company, Sanofi Genzyme, Daiichi Sankyo, BerGenBio, Genentech, Merus, AstraZeneca, Mirati Therapeutics	IC, IC, IC, IC, IC, IC, IC, IC	Speaker
Larkins	Erin	No Relationships		Speaker
Lemery	Steven	No Relationships		Speaker
Migali	Cristina	No Relationships		Speaker
Mishra-Kalyani	Pallavi	No Relationships		Speaker
Perlmutter	Jane	No Relationships		Speaker
Powles	Thomas	Roche, F. Hoffmann-La Roche, Roche, Exelixis, Seattle Genetics, AstraZeneca, Novartis, Eisai, Pfizer, Merck, F. Hoffmann-La Roche, Seattle Genetics, Inc., Merck, Pfizer, Ipsen Biopharm Limited, Pfizer, MSD, Mashup Communications, Merck, F. Hoffmann-La Roche, Ipsen Biopharm Limited, F. Hoffmann-La Roche, F. Hoffmann-La Roche, Johnson & Johnson Health Care Systems Inc., Seattle Genetics, Inc., MSD, AstraZeneca, Gilead Sciences Inc, Gilead Sciences Inc, Queen Mary University of London, AstraZeneca, Bristol-Myers Squibb, Ipsen Biopharm Limited, Novartis, EMD Serono, Inc., Bristol-Myers Squibb, EMD Serono, Inc., MSD, Pfizer, Eisai, Hoffmann-La Roche Limited, Gilead Sciences Inc, Incyte Corporation, Johnson & Johnson Health Care Systems Inc., Pfizer, Mashup Communications, Genentech, Mashup Communications, Exelixis, Exelixis, Astellas Pharma, Novartis, Astellas Pharma, AstraZeneca, Bristol-Myers Squibb	IC, IC, GC, GC, GC, IC, IC, IC, IC, IC, IC, GC, IC, IC, GC, IC, GC, IC, GC, GC, IC, GC, IC, GC, IC, IC, IC, E, GC, IC, IC, GC, GC, IC, IC, IC, IC, GC, GC, GC, IC, IC, GC, IC, GC, IC, IC, GC, GC, IC, IC, GC, GC, IC, IC, GC, GC, IC, GC	Speaker
Prowell	Tatiana	No Relationships		Speaker
Reuss	Joshua	Arcus Bioscience, Janssen Pharmaceuticals, AbbVie, Regeneron Pharmaceuticals, Gilead Sciences Inc, Exelixis, Seagen, Catalym, Daiichi Sankyo, Guardant Health, Summit Therapeutics, Genentech, AstraZeneca, Nuvalent, Novocure, Bristol-Myers Squibb	IC, IC, IC, IC, IC, GC, IC, IC, IC, IC, IC, GC, IC, GC, IC, IC	Speaker
Shah	Mirat	No Relationships		Speaker



FDA-AACR Workshop on HOW MUCH IS ENOUGH? TRIAL DESIGNS FOR TREATMENT REGIMENS WITH MULTIPLE PHASES

May 9, 2024, 9 a.m.–4 p.m. | Bethesda, MD

DISCLOSURE OF FINANCIAL RELATIONSHIPS

Last Name	First Name	All Relationships	Type	Role
Shan	Minghua	Moderna, Celldex Therapeutics, BeiGene, Ltd., Bayer, Intellia Therapeutics, Bayer	S, S, S, S, S, E	Speaker
Singh	Harpeet	No Relationships		Program Committee, Speaker
Song	Chi	No Relationships		Speaker
Sosa Mejia	Aaron	No Relationships		Speaker
Tendler	Craig	Janssen Research & Development, LLC	E	Speaker
Tolaney	Sara	Seattle Genetics, Mersana Therapeutics, Seattle Genetics, NanoString Technologies, Inc., CytomX Therapeutics, Genentech, Merck, SANOFI US SERVICES INC., Zentalis, Eli Lilly and Company, OncXerna, ARC Therapeutics, Myovant, Pfizer, Novartis Pharma, Zymeworks, Stemline Therapeutics Inc., Daiichi Sankyo Company, Merck, Gilead Sciences Inc, Cyclacel Pharmaceuticals Inc., AstraZeneca, Pfizer, Bayer HealthCare Pharmaceuticals Inc., Athenex Oncology, Zetagen, Genentech, Artios Pharmaceuticals, Ellipses Pharmaceuticals, Aadi Biopharma, 4D Pharma, Infinity Pharmaceuticals Inc., Eisai, Eli Lilly and Company, Bristol-Myers Squibb, OncoSec, SANOFI US SERVICES INC., Certara, Novartis Pharma, AstraZeneca, Gilead Sciences, Blueprint Medicines Corporation, Reveal Genomics, Eisai, Umoja Biopharmaceuticals, BeyondSpring Pharmaceuticals, Bristol-Myers Squibb, Dana-Farber Cancer Institute, Exelixis Inc.	GC, IC, IC, GC, IC, GC, GC, GC, IC, GC, IC, IC, IC, IC, IC, IC, IC, GC, GC, GC, GC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, GC, IC, IC, IC, IC, IC, GC, IC, IC, IC, IC, IC, GC, IC, IC, IC, IC, IC, IC, IC, IC, IC, GC, IC, IC, IC, IC, IC, IC, IC, IC, GC, E, GC	Speaker
Umoja	Rukiya	No Relationships		Staff
Vellanki	Paz	No Relationships		Speaker
Wethington	Stephanie	AstraZeneca	E	Speaker
Winson	Kathleen	Genentech	E	Speaker
Yarchoan	Mark	AstraZeneca, Exelixis, Genentech, Replimune, Hepion, Lantus, Bristol-Myers Squibb, Exelixis, Inctye, Genentech, Adevmtris Pharmaceuticals	IC, IC, IC, IC, GC, GC, GC, GC, OBO	Speaker

All of the relevant financial relationships listed for these individuals have been mitigated.